This patient is a 56-year-old woman with a history of IGG κ multiple myeloma diagnosed 15 years prior to admission. She had widespread lytic bone lesions and pathological fractures, which remarkably had not been accompanied by significant pain, but were mostly refactory to chemotherapy.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3716026 | PMC |
| http://dx.doi.org/10.3402/jchimp.v3i2.21419 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Retrospective claims data analysis of ASCT characteristics and costs for working-age, multiple myeloma patients in the US, 2017-2019.
Leuk Res Rep
December 2024
Department of Pharmaceutical Health Outcomes and Policy, University of Houston College of Pharmacy, United States.
Multiple myeloma (MM) is a rare hematologic malignancy with a 5-year survival rate of 52 %. For transplant-eligible MM patients, high-dose chemotherapy followed by autologous stem cell transplant (ASCT) is recommended. Given the complexities of the ASCT procedure, understanding patient-specific factors and their impact on treatment decisions is essential.
View Article and Find Full Text PDFDecreased STING predicts adverse efficacy in bortezomib regimens and poor survival in multiple myeloma.
Clin Exp Med
January 2025
Stem Cell Immunity and Regeneration Key Laboratory of Luzhou, The Affiliated Hospital, Southwest Medical University, Luzhou, Sichuan, China.
Purpose: STING (stimulator of interferon genes) is involved in viral and bacterial defense through interferon pathway and innate immunity. Increased susceptibility to infection is a common manifestation of multiple myeloma (MM). Thus, we aimed to explore the clinical significance and possible mechanism of STING in MM.
View Article and Find Full Text PDFTreatment efficacy for relapsed/refractory multiple myeloma patients with gain/amplification 1q21.
Chin Med J (Engl)
January 2025
Hematology Department, Qingdao Hospital, University of Health and Rehabilitation Science (Qingdao Municipal Hospital), Qingdao, Shandong 266011, China.
Multiple Myeloma in Italy: An Epidemiological Model by Treatment Line and Refractoriness Status.
Clin Lymphoma Myeloma Leuk
December 2024
Janssen-Cilag S.p.A., A Johnson & Johnson company, Milan, Italy.
Background: Multiple myeloma (MM) clinical management is challenging owing to its relapse and refractoriness to treatment. Understanding the treatment patterns and refractory dynamics is crucial for optimizing patient care. This study aimed to estimate the evolution of MM according to the treatment line and refractoriness status in Italy.
View Article and Find Full Text PDFExpert Opinion on Multiple Myeloma Treatment in Brazil in the Bispecific Antibody Era.
Clin Lymphoma Myeloma Leuk
December 2024
Universidade Federal do Rio de Janeiro -UFRJ, Rio de Janeiro, Brazil; Instituto Americas de Ensino, Pesquisa e Inovação, Rio de Janeiro, Brazil.
Multiple myeloma treatment has evolved rapidly with the development of novel targeted therapies. The paper outlines multiple myeloma epidemiology, current treatments, and recent advances, highlighting the role of bispecific antibodies. Brazilian authorities have approved 3 bispecific antibodies (teclistamab, elranatamab, and talquetamab) for relapsed/refractory multiple myeloma patients who have received at least three prior therapies.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!